NRSN

Announcements

Nothing here yet

Daily updates

• NeuroSense Therapeutics received FDA authorization to initiate the pivotal Phase 3 PARAGON study following favorable extended Phase 2b results published in JAMA Neurology.Sep 29, 2026
• NeuroSense refined its PrimeC development strategy for ALS and Phase 3 PARAGONSep 7, 2026

FDA designations

Nothing here yet

News

• NeuroSense advances PrimeC toward a new drug submission to Health Canada for ALSJul 22, 2026
• NeuroSense expanded its global IP protection with a granted Australian patent covering the PrimeC compositionFeb 10, 2026
• NeuroSense received FDA clearance to initiate pivotal Phase 3 trial for PrimeC in ALSNov 25, 2025
• NeuroSense's drug candidate shows early signals of benefit in Alzheimer's patient-derived neuronsSep 11, 2025
• NeuroSense Therapeutics successfully completes commercial manufacturing scale-up for PrimeC, preparing for Canadian market launch.May 7, 2025